$1.67
11.78%
Nasdaq, Apr 21, 07:53 pm CET
ISIN
US45254U1016
Symbol
IMRN
Sector
Industry

Immuron Limited Sponsored ADR Stock price

$1.89
+0.07 4.06% 1M
-0.08 3.91% 6M
+0.19 11.35% YTD
-0.52 21.46% 1Y
-1.06 35.83% 3Y
-0.46 19.45% 5Y
+1.75 1,248.22% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.18 10.70%
ISIN
US45254U1016
Symbol
IMRN
Sector
Industry

Key metrics

Market capitalization $11.06m
Enterprise Value $6.33m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.47
P/S ratio (TTM) P/S ratio 2.56
P/B ratio (TTM) P/B ratio 1.69
Revenue growth (TTM) Revenue growth 82.77%
Revenue (TTM) Revenue $4.32m
EBIT (operating result TTM) EBIT $-5.31m
Free Cash Flow (TTM) Free Cash Flow $-5.06m
EPS (TTM) EPS $-0.85
P/E forward negative
P/S forward 3.26
EV/Sales forward 1.17
Short interest 0.29%
Show more

Is Immuron Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Immuron Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Immuron Limited Sponsored ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Immuron Limited Sponsored ADR:

Buy
100%

Financial data from Immuron Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
4.32 4.32
83% 83%
100%
- Direct Costs 1.40 1.40
89% 89%
32%
2.91 2.91
79% 79%
67%
- Selling and Administrative Expenses 5.12 5.12
52% 52%
119%
- Research and Development Expense 3.10 3.10
27% 27%
72%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.31 -5.31
27% 27%
-123%
Net Profit -4.85 -4.85
89% 89%
-112%

In millions USD.

Don't miss a Thing! We will send you all news about Immuron Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immuron Limited Sponsored ADR Stock News

Neutral
GlobeNewsWire
11 days ago
Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in history March 2025 Quarter AUD$1.3 million up 2% on prior year March 2025 Year to Date AUD$5.3 million up 46% on prior year Australia March 2025 Quarter AUD$0.8 million down 8% on prior year March 2025 Year to Date AUD$3.7 million up 34% on prior year North America March 2025 Quarter ...
Neutral
GlobeNewsWire
about 2 months ago
MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sal...
Neutral
GlobeNewsWire
3 months ago
Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcp December 2024 Half Year AUD$4.0 million up 70% on pcp Australia December 2024 Quarter AUD$1.9 million up 83% on prior quarter, up 314% on pcp December 2024 Half Year AUD$2.9 million up 54% on pcp North America December 2024 Quarter AUD$0.7 million up 43% on prior quarter, up 141% on pcp Decemb...
More Immuron Limited Sponsored ADR News

Company Profile

Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the following segments: Research and Development, and HyperImmune Products.The Research and Development segment involves the R&D projects performed in Australia, Israel, and United States. The HyperImmune Products segment comprises of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.

Head office Australia
CEO Steven Lydeamore
Founded 1994
Website www.immuron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today